The Impact of Intravenous Bendavia™ on Endothelial Reactivity Dysfunction in Cigarette Smoking

Healthy Volunteers Clinical Trial

Official title:

A Phase 1, Placebo-Controlled Trial to Evaluate the Impact of Intravenous (IV) Bendavia™ (MTP-131) on Endothelial Reactivity Dysfunction Induced by Cigarette Smoking

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01518985
• Other study ID #: SPIRI-120
• Status: Completed
• Phase: Phase 1
• First received: January 23, 2012
• Last updated: April 17, 2012
• Start date: January 2012
• Est. completion date: March 2012

Study information

• Verified date: April 2012
• Source: Stealth BioTherapeutics Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This will be a phase 1 randomized, double-blind, 2-period, 2-sequence crossover trial enrolling 6 healthy volunteers to assess the impact of IV-administered Bendavia on the endothelial dysfunction induced by a single cigarette.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: March 2012
• Est. primary completion date: March 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Healthy adult male smokers between 18 and 65 years of age with signed informed consent

Exclusion Criteria:

• Serum sodium level below the lower limit of sites' clinical laboratory normal range at screening, D-1 and 6

• Cholesterol level = 240 mg/dL

• Hypertension (blood pressure SBP > 140, DBP > 90 mmHg)

• Body mass index < 18 or > 32 kg/m2,

• Creatinine clearance calculated by the Cockcroft and Gault method calculated to be < 90 mL/min,

• Additional laboratory abnormalities determined as clinically significant by the Principal Investigator at laboratory screening

• Clinically significant abnormalities on physical examination,

• History or evidence of renal, hepatic, pulmonary (including chronic asthma), endocrine (e.g., diabetes), central nervous, or gastrointestinal (including an ulcer) system dysfunction,

• History of seizures or history of epilepsy,

• History of serious (Principal Investigator judgment) mental illness,

• Receipt of investigational medicinal product within 30 days prior to the planned date of study drug administration,

• Positive serology for human immunodeficiency virus type 1 or 2, or hepatitis B surface antigen,

• Fever > 37.5°C at the time of planned dosing,

• Suspicion, or recent history, of alcohol or substance abuse,

• Donated blood or blood products within the past 30 days,

• Employee or family member of the investigational site,

• Subjects who are either unwilling to agree to refrain from use or found to be using Nicotine (or nicotine products) including cigarettes from 12 hours prior to start of each study drug infusion through to the completion of endothelial function testing, Alcohol, Caffeine, Xanthine-containing food or beverages and over-the-counter medications with the exception of Tylenol from 24 hours prior to dosing and throughout the confinement periods, Supplementary antioxidant vitamins from 7 days prior to dosing and throughout the confinement periods, Prescription medications from 14 days prior to and 7 days post treatment

• Subjects having previous exposure to Bendavia.

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Healthy Volunteers

Intervention

Drug:
• Bendavia
Bendavia for infusion Intravenous infusion (0.25mg/kg/hr) for 4 hours
• Sterile saline (0.9%)
Sterile saline for infusion (0.9%) Intravenous infusion for 4 hours

Other:
• Cigarette smoking
One unfiltered cigarette will be smoked at approximately 30 minutes post-study-drug administration start.

Locations

Country	Name	City	State
United States	Clinical Pharmaology of Miami	Miami	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Stealth BioTherapeutics Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Analysis of variance (ANOVA) between group mean endothelial function (EndoPAT Index) following smoking a single cigarette with and without Bendavia	Endothelial function will be determined using EndoPAT 2000 (Itamar Medical Ltd) prior to and after smoking of one unfiltered cigarette and prior to and after initiation of study drug. Group comparison of endothelial function (EndoPAT Index) between placebo and active study drug within a subject will be performed.; EndoPAT quantifies the endothelium-mediated changes in vascular tone. A post-occlusion to pre-occlusion ratio is calculated providing the EndoPAT index.	Baseline, +30, +60, +90 minutes post-study-drug administration start	No
Secondary	Anova between group mean inflammatory laboratory marker (hs-CRP; mg/L) after smoking one cigarette with and without Bendavia	hs-CRP will be evaluated prior to and after smoking of one unfiltered cigarette and prior to and after initiation of study drug. Group comparison of hs-CRP levels between placebo and active study drug within a subject will be performed.	Baseline to 24 hours post-study-drug administration	No
Secondary	ANOVA between group means of urinary 8-isoprostane (ng/mg of creatinine) after smoking one cigarette with and without Bendavia	8-isoprostane will be measured prior to and after smoking of one unfiltered cigarette and prior to and after initiation of study drug. Group comparison of laboratory results between placebo and active study drug within a subject will be performed.	Baseline to 48 hours post-study-drug administration	No
Secondary	Number adverse events with and without Bendavia	Adverse events will be tabulated by treatment group. No statistical analysis will be preformed.	Baseline to Study Day 10	Yes
Secondary	Assessment of Bendavia exposure measured by area Under the Curve (AUC; ng*hr/mL)	Bendavia levels will be measured and pharmacokinetic parameters reported.	Baseline to 48 hours post-study-drug administration	No
Secondary	ANOVA between group means of urinary 8-hydroxy-2'-deoxyguanosine (pg/mL) after smoking one cigarette with and without Bendavia	8-hydroxy-2'-deoxyguanosine will be measured prior to and after smoking of one unfiltered cigarette and prior to and after initiation of study drug. Group comparison of laboratory results between placebo and active study drug within a subject will be performed.	Baseline to 48 hours post-study-drug administration	No